Logo

Sun Pharmaceuticals' Absorica Received the US FDA's Approval for Severe Recalcitrant Nodular Acne

Share this

Sun Pharmaceuticals' Absorica Received the US FDA's Approval for Severe Recalcitrant Nodular Acne

Shots:

  • The approval is based on the study assessing of Absorica vs another isotretinoin 925 patients aged 12 years and older in patients with severe recalcitrant nodular acne
  • Study results: Mean reduction in nodular lesions (-15.68 vs -15.62); 90% reduction in total nodular lesion count (70% vs 75%)
  • Absorica ((isotretinoin) is a prescription medicine granted patients aged 12 years of age and older treat the most severe form of acne nodular acne and also have a boxed warning for embryo-fetal toxicity – contraindicated in pregnancy

Click here to­ read full press release/ article | Ref: Optumrx | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions